68Ga-OPS202
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for 68Ga-OPS202, covering 2019-10-02 to 2021-01-14. Get the full timeline:
Most recent: Clinical Trial Update: To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) [Phase 2]